Attached files

file filename
EX-99.1 - CHEMICAL FINANCIAL EXHIBIT 99.1 TO FORM 8-K - TCF FINANCIAL CORPchemex991_012317.htm

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 17, 2017

Chemical Financial Corporation
(Exact Name of Registrant as
Specified in its Charter)

  Michigan
(State or Other Jurisdiction
of Incorporation)
000-08185
(Commission
File Number)
38-2022454
(IRS Employer
Identification No.)
 

 

235 E. Main Street
Midland, Michigan
(Address of Principal Executive Offices)

 

 
48640
(Zip Code)
 

Registrant's telephone number, including area code:  (989) 839-5350

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On January 17, 2017, Jeffrey L. Tate was appointed to the Board of Directors of Chemical Financial Corporation ("Chemical") effective March 1, 2017. It is expected that Mr. Tate will be appointed to the Audit Committee and the Risk Management Committee.

Mr. Tate is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding pursuant to which Mr. Tate was selected as a director.

Mr. Tate will be entitled to receive compensation for his service as a director consistent with the compensation paid to other directors as described in Chemical's Proxy Statement for Chemical's April 18, 2016 annual meeting of shareholders.

Item 7.01 Regulation FD Disclosure.

 

On January 23, 2017, Chemical issued the press release attached as Exhibit 99.1 to this Form 8-K, which is here incorporated by reference. The information under this Item 7.01 and the Exhibit are furnished to, and not filed with, the Commission.

 

Item 9.01. Financial Statements and Exhibits.
     
  (d) Exhibits:
     
  99.1 Press Release dated January 23, 2017.  This Exhibit is furnished to, and not filed with, the Commission.
     

 

 

 2 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  January 23, 2017 CHEMICAL FINANCIAL CORPORATION
(Registrant)
     
     
    /s/ David B. Ramaker
         David B. Ramaker
     Chief Executive Officer and President

 

 

 3 

 

EXHIBIT INDEX

 

Exhibit Number   Document
     
99.1   Press Release dated January 23, 2017.  This Exhibit is furnished to, and not filed with, the Commission.